Figure . PINNACLE FLX (Protection Against Embolism for Non‐valvular AF [Atrial Fibrillation] Patients: Investigational Device Evaluation of the Watchman FLX LAA [Left Atrial Appendage] Closure Technology) secondary efficacy end point analysis.

A, The prespecified secondary efficacy end point was met with a rate of 3.4% at 2 years and an upper 1‐sided 95% confidence bound (UCB) of 5.3%, which was below the performance goal of 8.7%. B, Kaplan‐Meier estimates of the rate of ischemic stroke or systemic embolism through 2 years.